Jannah Theme License is not validated, Go to the theme options page to validate the license, You need a single license for each domain name.

AGC Biologics is investing in new viral vector suspension capabilities at US Cell & GeneHub

Article content

New technologies and capacities help CDMO’s advanced treatment campus meet growing market demand

Advertising 2

Article content

SEATTLE, May 17, 2022 (GLOBE NEWSWIRE) — AGC Biologics, the world’s leading biopharmacy contractor (CDMO), today adds viral vector suspension technology and gene therapy development and manufacturing capabilities to its commercial facilities. I announced that. Grade campus in Longmont, Colorado, USA. Launched online in the third quarter of 2022, these new features complement the provision of campus adherent viral vectors and cell therapies. AGC Biologics can now offer a variety of end-to-end cell and gene therapy services. site.

North America has historically been home to more advanced therapies and regenerative medicine developers than any other region in the world.In addition, 2021 Q3 CL & Gene Therapy Market Outlook According to industry standard research (ISR) reports, viral vectors are the most common one that drug developers need from CDMO. This expansion will more than double the viral vector capacity of the site and help AGC Biologics meet the demands of these markets.

Advertising 3

Article content

“This investment will help AGC Biologics meet the needs of gene therapy developers at its new central location in North America,” said Patricio Massera, CEO of AGC Biologics. “Combining these new features and technical expertise at the Longmont Campus with the experience of the Milan facility’s lentiviral vector platform and its extensive gene therapy CDMO, almost all viral vector programs being developed around the world. Will be able to support. “

The expansion of viral vector suspensions is part of AGC Biologics’ investment of more than $ 30 million in the new Longmont campus. New suspension features include full complement of bioreactor size for product development (AMBR, 10L, and 50L) and full range of commercial manufacturing capacity (50L, 200L, 500L, and 2000L), site. Allows you to provide support for the entire life cycle of the product.

Advertising 4

Article content

Tony Fraij, General Manager of AGC Biologics Longmont, said: “This latest investment will help complete the services offered on this campus. Now, with a complete feature suite and extensive expertise of scientists, we are developing and developing virtually any type of viral vector or cell therapy. We can support manufacturing projects. ”

AGC Biologics acquired the Longmont Campus in August 2021 and immediately appointed Fraij, a 20-year veteran with experience leading operations in several global life sciences organizations. The company previously acquired a cell and gene therapy site in Milan, Italy from MolMed SpA in 2020. The technical expertise of the AGCBiologicsMilan team will play an important and beneficial role in launching new viral vector functions in Longmont. In just a few years, the company has built a strong global cell and gene therapy network of services, capabilities and scientists. AGC Biologics is one of the few CDMOs that offers end-to-end advanced cell therapy on two continents.

Advertising 5

Article content

For more information on corporate viral vector services, please visit www.agcbio.com/abilities/viral-vector. For more information on AGC Biologics’ cell therapy products, please visit www.agcbio.com/abilities/cell-therapy.

About AGC Biologics

AGC Biologics is the world’s leading biopharmacy contracting organization (CDMO), with a strong commitment to providing the highest standards of service in collaboration with clients and partners at all stages. We provide world-class development and production of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the United States, Europe, and Asia, with cGMP-compliant facilities in Seattle, Washington. Boulder and Longmont, Colorado. Copenhagen Denmark; Heidelberg, Germany; Italy, Milan; Chiba, Japan and we currently employ more than 2,000 people worldwide. Continued innovation efforts drive technological creativity to solve the client’s most complex challenges, such as rapid projects and specialization of rare diseases. AGC Biologics is the perfect partner. For more information, please visit www.agcbio.com.



Comment Comment

Postmedia promises to maintain a forum for lively yet civil discussions and encourages all readers to share their views on our articles. Moderation can take up to an hour for comments to appear on your site. Comments are relevant and should be stored with respect. You have enabled email notifications. You will now receive an email when you receive a reply to a comment, when the comment thread you are following is updated, or when a user follows a comment. For more information and details on how to adjust your email settings, see Community Guidelines.

AGC Biologics is investing in new viral vector suspension capabilities at US Cell & GeneHub

Source link AGC Biologics is investing in new viral vector suspension capabilities at US Cell & GeneHub

Related Articles

Back to top button